"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Descriptor ID |
D009103
|
| MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
| Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 3 | 2 | 5 |
| 1999 | 4 | 0 | 4 |
| 2000 | 4 | 2 | 6 |
| 2001 | 7 | 1 | 8 |
| 2002 | 8 | 1 | 9 |
| 2003 | 11 | 1 | 12 |
| 2004 | 10 | 1 | 11 |
| 2005 | 7 | 1 | 8 |
| 2006 | 1 | 0 | 1 |
| 2007 | 5 | 1 | 6 |
| 2008 | 6 | 0 | 6 |
| 2009 | 8 | 1 | 9 |
| 2010 | 7 | 0 | 7 |
| 2011 | 9 | 1 | 10 |
| 2012 | 5 | 1 | 6 |
| 2013 | 9 | 1 | 10 |
| 2014 | 10 | 1 | 11 |
| 2015 | 5 | 1 | 6 |
| 2016 | 7 | 0 | 7 |
| 2017 | 13 | 2 | 15 |
| 2018 | 6 | 3 | 9 |
| 2019 | 15 | 1 | 16 |
| 2020 | 18 | 2 | 20 |
| 2021 | 15 | 1 | 16 |
| 2022 | 18 | 0 | 18 |
| 2023 | 19 | 0 | 19 |
| 2024 | 18 | 3 | 21 |
| 2025 | 16 | 0 | 16 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases. JAMA Neurol. 2026 May 01; 83(5):461-470.
-
Telomere length as a marker of biological age in paediatric multiple sclerosis. J Neurol Neurosurg Psychiatry. 2026 Mar 13; 97(4):302-308.
-
Genome-wide discovery of multiple sclerosis genetic risk variant allelic regulatory activity. G3 (Bethesda). 2025 11 12; 15(11).
-
Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis. Ann Neurol. 2026 Mar; 99(3):715-729.
-
Epigenetic age and telomere length correlations in pediatric-onset multiple sclerosis. Mult Scler. 2025 Dec; 31(14):1641-1650.
-
The hidden toll: Atrophy of key central nervous system relays in African American women with multiple sclerosis. J Neuroimmunol. 2025 Dec 15; 409:578776.
-
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry. J Child Neurol. 2026 Apr; 41(4):545-555.
-
Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025 Dec; 104:106750.
-
Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021. Mult Scler. 2025 Nov; 31(13):1595-1599.
-
Epigenetic Aging in Pediatric-Onset Multiple Sclerosis. Neurology. 2025 Jun 24; 104(12):e213673.